Psychedelics, With a Focus on Psilocybin: Issues for the Clinician

Amir Garakani, Jeanne L. Alexander, Calvin R. Sumner, Janet H. Pine, Lawrence S. Gross, Charles L. Raison, Scott T. Aaronson, David A. Baron

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

There has been a burgeoning interest in psychedelics among the public, state legislatures, psychiatrists and other clinical providers, and within the research community. Increasing numbers of studies evaluating psychedelics for depression, anxiety, posttraumatic stress disorder, and substance use disorders have been conducted or are underway. While discussing psychedelics in general, the focus of this paper is on psilocybin and its mechanism, how it exerts a psychedelic effect, dosing, and a review of the treatment studies of psilocybin, which were primarily for treatment-resistant depression and cancer-related anxiety. Future directions and potential limitations of studying and regulating psilocybin and other psychedelics are also discussed.

Original languageEnglish
Pages (from-to)345-353
Number of pages9
JournalJournal of Psychiatric Practice
Volume29
Issue number5
DOIs
StatePublished - 1 Sep 2023

Fingerprint

Dive into the research topics of 'Psychedelics, With a Focus on Psilocybin: Issues for the Clinician'. Together they form a unique fingerprint.

Cite this